Pharmacogenetic testing to broaden patient eligibility for mavacamten

European Heart Journal - Cardiovascular Pharmacotherapy

14 November 2024

Organised by:

Read full article

Contributors

Lorenz Van der Linden

Lorenz Van der Linden

Author

University Hospitals (UZ) Leuven Leuven , Belgium

Lucas Van Aelst

Lucas Van Aelst

Author

Iacopo Olivotto

Iacopo Olivotto

Author

University of Florence Florence , Italy

You may be interested in

Congress Presentation

Clinical characteristics and long-term prognosis of patients with heart failure with reduced, mildly reduced, and preserved left ventricular ejection fraction secondary to Chagas cardiomyopathy

Congress Presentation

Presence of heart failure in pts with coronary artery disease and artery hypertension

Congress Session

Bridging gaps in heart failure care: primary care trends, exercise, kidney function, and global health perspectives

ESC 365 is supported by

novartis

Explore sponsored resources